Articles tagged with Drug Combinations
New research suggests that cannabis use can lead to harmful drug-drug interactions by interfering with two families of enzymes that metabolize a wide range of drugs. This could result in unintended side effects such as toxicity or accidental overdose, particularly for older individuals using medications.
Research shows that common medicines have distinct effects on gut bacteria, with some having beneficial and others detrimental impacts. The study found associations between certain medications and changes to the gut microbiome, particularly with statins and gastric acid medication.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
Researchers at UConn Health have discovered that eliminating senescent cells in human fat tissue can alleviate signs of diabetes and improve insulin sensitivity. The study suggests that clearing away these dysfunctional cells could lead to game-changing new treatments for Type 2 diabetes.
Researchers are modifying an arm of a worldwide clinical trial to evaluate a combination of drugs targeting two brain proteins: amyloid and tau. The Tau NexGen Trial aims to test the effectiveness of these treatments in slowing disease progression by targeting both Alzheimer's disease pathologies.
Researchers have discovered a potential new treatment for COVID-19 by targeting the pentose phosphate pathway, which is necessary for SARS-CoV-2 replication. The study found that inhibiting this pathway with benfooxythiamine suppresses viral replication and reduces virus production.
New study reveals that blocking interleukin-23 is more effective than targeting both interleukin-23 and interleukin-12 in treating psoriasis. Interleukin-12, previously thought to contribute to the disease, actually protects against it by maintaining normal skin cell function.
A research team from the University of Zurich has identified a common genetic variant in the AQP1 gene that affects treatment efficacy and patient survival on peritoneal dialysis. Patients carrying this variant have a higher risk of death, but researchers found a way to circumvent the problem using colloid osmotic agents.
A systematic review of tobacco cessation pharmacotherapies and e-cigarettes found that combined treatments, particularly varenicline and nicotine replacement therapy (NRT), were the most effective in helping people quit smoking. E-cigarettes showed promise but require further research to establish their safety.
Researchers at NTNU have developed a promising new drug combination that effectively suppresses SARS-CoV-2 infection by targeting the TMPRSS2 factor. The combination of nafamostat and Pegasys (IFNα) shows great potential in treating COVID-19, with low doses needed for clinical advantages.
A novel combination of abiraterone acetate and prednisolone has been shown to prolong survival in patients with hormone/castration-sensitive prostate cancer. Studies PEACE-1 and STAMPEDE found that the addition of these drugs to standard therapy lengthened survival compared to standard therapy alone.
A new study from Yale University found that adding oleclumab or monalizumab to durvalumab improves progression-free survival for patients with locally advanced non-small cell lung cancer. The combination reduced the risk of disease progression or death by 56% and 35%, respectively.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
The study found that patients with low risk of exacerbations do not benefit from low to moderate dose inhaled corticosteroids, while high doses are associated with severe side effects. Tailoring treatment according to patient characteristics, such as age and blood cell count, can minimize over- and underuse of inhaled corticosteroids.
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.
Researchers have developed an immunotherapy strategy that combines three drugs to boost the immune system against tumors. The new therapy showed promising results in mice, with pancreatic tumors shrinking or disappearing completely in about half of the animals.
Researchers identified a novel drug duo that exploits a weakness in SCLC's reproduction process, increasing replication stress and damaging DNA. The berzosertib-topotecan combination helped improve symptoms in over one-third of patients in a clinical trial.
A combination of metoclopramide and diphenhydramine has been shown to reduce headache pain by more than five points in people who experienced a head trauma. However, the study's results may not be generalizable due to the participants' limited socioeconomic access.
Researchers have identified a potential revolutionary drug combination that is 'spectacularly effective' in eradicating DIPG cancer cells. The treatment, a combination of difluoromethylornithine (DFMO) and AMXT 1501, was found to be highly effective in animal studies and pre-clinical testing.
Researchers from NUS utilised a ground-breaking AI platform to derive an optimal combination of available therapies against SARS-CoV-2, resulting in a treatment that was 6.5 times more effective than remdesivir alone. The top-ranked combination included the drugs remdesivir, lopinavir, and ritonavir at specific doses.
Researchers have discovered a combination of MEK and SHP2 inhibitors effective in targeting the mechanism driving cancer growth in malignant peripheral nerve sheath tumours. The treatment has shown promise in both cell culture and mouse models, offering hope for improved treatment outcomes for patients.
Scientists have developed a technique that quickly identifies optimal synergistic combinations of anticancer drugs, reducing tumour growth by 80% and outperforming chemotherapy. The technology, called TGMO, achieves results in under two weeks, paving the way for personalized, effective, and safe cancer treatment.
A joint study by University of Cologne researchers predicts the outcomes of combining certain antibiotics using mathematical models. The scientists found that interactions between antibiotics are often caused by bottlenecks in the translation cycle, allowing them to predict the effects of antibiotic combinations without trial and error.
Biomedical engineers at Duke University created a combination molecule featuring GLP-1 and FGF21 that controls blood sugar levels and promotes weight loss in mice for up to a week after a single injection. The slow-release ELP linker ensures stable drug release over time.
A study by Radboud University Medical Center found that a single pill of dolutegravir per day is equally effective as a combination therapy in children, reducing dosage complexity and increasing treatment accessibility. This simplified dosing regimen has been integrated into World Health Organization guidelines and FDA approval.
A NUS-led team has developed an artificial intelligence platform called IDentif.AI to rapidly identify optimal drug combination therapies for infectious diseases. The platform uses machine learning to examine billions of possible combinations and doses, resulting in unprecedented speed and accuracy in discovering new treatments.
Researchers at Duke-NUS Medical School in Singapore have identified a common therapeutic vulnerability for a genetically diverse and deadly form of leukemia. The study reveals that the polycomb repressive complex plays a critical role in driving progression to blast crisis, a nearly always fatal stage of the disease.
The Akay Lab has developed a new microfluidic brain cancer chip that can simultaneously administer multiple drugs and assess their response to glioblastoma cells. The device enables fast drug combination testing in as little as two weeks, potentially improving patient survival rates.
New study reveals antibiotic tolerance promotes the evolution of antimicrobial resistance even under combination drug treatments. The results suggest that designing antibiotic treatments must consider drug tolerance to prevent the emergence of resistance.
A new treatment option for Ewing sarcoma is proposed by combining chemotherapy drug imatinib with diabetes medication metformin, according to Houston Methodist researchers. The combination has shown potential in treating the aggressive tumor in clinical trials.
A University of Michigan AI solution, INDIGO, can predict how current drugs can be combined to create more effective tuberculosis treatments. The tool identified several strong combinations, including those with antipsychotics and antimalarials.
Researchers identified a panobinostat-marizomib combination that effectively kills childhood brain cancer cells and counters genetic mutations. The study uncovered a previously unrecognized vulnerability in cancer cells, which may lead to new strategies against the disease.
A phase-3 trial shows that combining rituximab with ibrutinib keeps patients disease-free for nearly three years and improves overall survival rates. The new treatment is more effective and better tolerated than traditional chemotherapy, revolutionizing the standard of care for chronic lymphocytic leukemia.
Boston University researchers suggest making buprenorphine available behind the counter with age and quantity limitations to increase access for treating opioid use disorder. This could lead to reduced health costs, lower drug-related crime, and more lives saved.
Researchers at Beth Israel Deaconess Medical Center have identified novel combinations of antifungal and antibacterial drugs that demonstrate activity against multidrug resistant Candida auris. The study used a modified inkjet printer to test multiple combinations, finding three effective treatments in under two hours.
Researchers at UNIGE have created a 3D cell co-culture platform to test personalized cancer treatments, demonstrating that low-dose combinations of drugs are more effective than high-dose monotherapies. The platform opens the door to rapid and cost-effective treatment options for various types of tumors.
Researchers at UCLA have found a way to significantly reduce the duration of tuberculosis treatment using artificial intelligence and data analysis. The new approach identifies synergistic drug combinations that work together to cure TB more quickly and effectively.
A new study by researchers at the University of Illinois found that combining two cancer drugs, selinexor and 4-OHT, may prevent endocrine resistance in breast tumors. The treatment protocol was more effective than either drug alone in reducing tumor cells' viability.
A new UK-based study reveals that alcohol, cannabis, MDMA, and cocaine are the most commonly combined with sex. The research found that people of all genders and sexual orientations engage in substance-linked sex, but gay and bisexual men are more likely to do so.
A new study published in Sleep found a 250% increase in Americans taking opioids with benzodiazepines or Z-drugs between 1999 and 2014. This alarming trend is associated with increased risks of serious adverse outcomes, including breathing problems and death.
Scientists have found a drug combination that can halt the progression of fibrosis, a condition responsible for almost half of all deaths. The study, published in European Urology, tested a combination of phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators on cells and animals.
The Quadratic Phenotypic Optimization Platform (QPOP) uses AI to analyze small datasets and design optimal drug combinations based on real experimental data. This approach can optimize and personalize combination therapy for individual patients with complex diseases, such as multiple myeloma.
A clinical study using the CURATE.AI platform successfully treated a patient with metastatic castration-resistant prostate cancer, completely halting disease progression. The AI platform continuously optimised novel drug combination dosages to achieve a durable response, allowing the patient to resume an active lifestyle.
Analysis of Medicare Part D spending reveals $925 million difference between brand-name combo drugs and using generic components. Prescriber education and substitution policies can help reduce costs by promoting generic substitution.
Researchers at NUS have developed an AI technology platform that can quickly determine the most effective drug combination for a patient. The Quadratic Phenotypic Optimisation Platform (QPOP) uses small experimental data sets to identify effective drug combinations and personalized treatment options.
Researchers developed QPOP, a computational platform that identifies effective drug combinations against bortezomib-resistant MM. The platform successfully predicted dosages for combination therapies, leading to reduced tumor size and prolonged survival in mouse models.
A team of researchers developed an AI system called Decagon to predict potential side effects from drug combinations. By analyzing cellular machinery interactions and known associations between drugs and side effects, the system identified patterns and predicted previously unseen consequences.
A large-scale screening of antibiotic combinations has identified over 500 pairs that improve antibiotic effectiveness against multi-drug resistant bacteria. These pairings could help combat antibiotic resistance by selectively targeting harmful bacterial species, reducing the development of resistance and its transmission.
Researchers at EMBL screened over 1100 treatment conditions using a novel microfluidic device, discovering individualized cancer therapies for each patient. The device was tested on four patient biopsies, showing highly reproducible results and potential for personalized medicine.
Monash researchers have created a computer model that can predict which combination of drugs will be most effective in treating triple negative breast cancer. The model, developed using genetic and treatment data from hundreds of patients, reveals a previously unknown combination of two drugs that may be successful.
Researchers at the University of Pennsylvania School of Medicine found that a two-drug combination of mifepristone and misoprostol can effectively complete miscarriages, reducing the need for surgical intervention. The study showed that 91.2% of women experienced gestational sac expulsion after receiving the treatment.
A new study found that combination CC+AZ therapy is safe and effective for patients with elevated estradiol or low testosterone/estradiol ratios. The treatment improves testosterone levels and reduces estradiol levels by lowering conversion of testosterone to estradiol.
Researchers at the University of Minnesota Medical School discovered an unrecognized cyclic pathway structure within the folate biosynthesis pathway, allowing each drug to enhance the activity of the other. This new mechanism has the potential to open doors for identification of other synergistic drug combinations.
The evidence for India's top-selling diabetes drug combinations falls short of WHO standards, potentially putting patients at risk. Only one trial assessed the balance between pros and cons, while 18 were sponsored by multinational corporations or conducted by pharmaceutical companies.
Many epilepsy patients receive antiepileptic and non-epilepsy drugs that can interact, altering the effectiveness of one or both types of medications. The study found over 1 in 5 patients taking such combinations may experience reduced efficacy or increased toxicity.
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of bet hedging. Genetic variations in cancer lead to differences in drug response, making combination therapy more effective by boosting the likelihood that a patient will benefit from at least one drug.
Researchers demonstrate an engineering approach to combine four drugs and control parasitic worms, a major breakthrough in treating nematode infections. The technique, developed by Chih-Ming Ho, uses a feedback system to quickly identify potent drug combinations that are effective on a small-animal model organism.
Researchers at CHEO identified sedation medications and practices associated with the best clinical outcomes, making ketamine-alone a logical choice for providing procedural sedation to children. The study found that choice of sedation medication had the biggest impact on the incidence of adverse events.
Computer simulations show moxifloxacin kills bacteria more quickly and performs better when doses are missed, making it a superior option for tuberculosis treatment. The research also found that levofloxacin killed bacteria more quickly than gatifloxacin.
A clinical trial at the University of Cincinnati is investigating a drug combination therapy using sirolimus and resveratrol to induce disease remission in patients with lymphangioleiomyomatosis (LAM). The study aims to identify a regimen that will eliminate LAM cells, which currently only suppress growth.